Thank you to Nasdaq for sharing the exciting news of the extension to our series B financing at the MarketSite in Times Square! #AI #ML #Drugdiscovery
Iambic Therapeutics
Biotechnology Research
San Diego, CA 7,352 followers
Charting new paths to superior medicines
About us
Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.
- Website
-
http://www.iambic.ai
External link for Iambic Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, CA
- Type
- Privately Held
- Founded
- 2019
- Specialties
- machine learning, artificial intelligence, drug discovery, catalysis, materials, sustainability, chemistry, biochemistry, pharmaceuticals, polymers, quantum mechanics, molecular simulation, batteries, and energy
Locations
-
Primary
Get directions
San Diego, CA, US
-
Get directions
5627 Oberlin Dr
Suite 120
San Diego, California 92121, US
Employees at Iambic Therapeutics
-
Sophie Coon
Innovative Product Leader: Driving Results in Technical Environments with Cross-Disciplinary Expertise | Artist at Sophie Coon Studios
-
Jose Alberto Quiroz Ramos
Executive Director at Iambic Therapeutics
-
John Lamoureux
Senior IT Leader | Business Relationship Management | Infrastructure & Operations | Security | Life Sciences | Biotechnology | Pharma
-
John Huang
Vice President of Biology at Iambic
Updates
-
Delighted to have Brian Orelli, PhD from BiotechTV visit Iambic’s San Diego HQ to meet with our CEO Thomas Miller to discuss the recent extension to our Series B financing, expanding pipeline, and AI-driven discovery platform that enables us to advance highly differentiated drug development candidates to clinic in a fraction of the industry average. See the full interview below. https://lnkd.in/gFt29wNQ
-
Thank you to Andrew Dunn for this reporting and the opportunity to discuss how Iambic has realized the remarkable power of AI and machine learning - integrated with automated experimentation - to rapidly discover, design and deliver to the clinic highly differentiated drug development candidates. #AI #ML #drugdiscovery #endpointsnews
In the first months of building their startup, Thomas Miller and Fred Manby asked Derek Lowe to join their scientific advisory board. Lowe, as most in the industry know, writes an influential blog on the industry's happenings, particularly in dispensing a sobering, grounded view on the AI hype surrounding biology. By bringing in Lowe — the only AI biotech that Lowe has formally advised — Iambic Therapeutics built some pragmatism into its DNA. “It hasn’t always been the most cheerful advice for any computational company to hear,” Lowe said in an interview. “I’m not going to be someone who just comes in and tells them, ‘Yeah, looks great. You guys are wonderful.’ You can get a lot of people doing that for you.” That level-headedness carries through today, as the Iambic team is focused on making real drugs with its AI software. In my latest for Endpoints News, I visited Iambic's labs to see how its software works and the next steps for Miller and Manby's fast-growing startup:
How two academic chemists turned San Diego startup Iambic into an AI force
https://endpts.com
-
Iambic Therapeutics reposted this
Thrilled to announce that we have closed a $50 million extension to our series B financing, with the total for the round now exceeding $150 million. Proceeds will be used to broaden our pipeline of AI-discovered clinical and pre-clinical oncology programs and further advance our AI/ML and automated experimentation platform. We want to thank Mubadala Capital and Exor Ventures for leading the round and all of the new and existing investors for their participation. Learn more in today’s press release: https://lnkd.in/eQk6jD96 #AI #ML #Drugdiscovery
-
-
Thrilled to announce that we have closed a $50 million extension to our series B financing, with the total for the round now exceeding $150 million. Proceeds will be used to broaden our pipeline of AI-discovered clinical and pre-clinical oncology programs and further advance our AI/ML and automated experimentation platform. We want to thank Mubadala Capital and Exor Ventures for leading the round and all of the new and existing investors for their participation. Learn more in today’s press release: https://lnkd.in/eQk6jD96 #AI #ML #Drugdiscovery
-
-
At Iambic Therapeutics we consider AI to be a great enabler for drug discovery, as we aim to use it to make better medicines for patients with a higher probability of success on a faster timeline. It is not about fully automating drug discovery but using AI to more rapidly search chemical space for a wide array of potential targets so our team can more efficiently identify promising development candidates. Thank you to Brian K. Buntz for capturing this distinction in this piece in Drug Discovery & Development. https://lnkd.in/eFcAPsYG #AI #DrugDiscovery #NVIDIAAI
Iambic and NVIDIA: Using AI to chart a faster course for drug discovery - Drug Discovery and Development
https://www.drugdiscoverytrends.com
-
Iambic Therapeutics CEO Thomas Miller participated in last week’s White House Office of Science and Technology Policy meeting, AI Aspirations: R&D for Public Missions, joining leaders from government, industry and academia in a discussion on AI’s critical role in creating new innovations to benefit society. Miller joined fellow panelists Trevor Mundel, Houman Ashrafian, Sergei Yakneen, David Strauss, MD, PhD, and David Gunning to discuss how AI can speed the pace of drug discovery and development and find new treatments for patients. This future has arrived at Iambic, where our lead AI-discovered cancer development candidate reached the clinic in under 24 months, four years faster than the average for new drug programs. Thank you to Arati Prabhakar for hosting the program and to all of the participating leaders from the Administration and Congress including: Gina Raimondo, shalanda young, Robert C. Hampshire, Robert Califf, Don Beyer, @amyklobuchar, @markwarner and @secCardona. #AI #DrugDiscovery #AIgov #arpah
-
-
Congratulations to our CEO Thomas Miller for being named a winner of EY’s Entrepreneur Of The Year® 2024 Pacific Southwest Award. This award ultimately reflects the extraordinary team at Iambic Therapeutics that is developing breakthrough AI technologies to create urgently needed medicines. With our first oncology drug candidate (IAM1363) in clinical trials and others advancing through our ever-expanding pipeline, we couldn’t be more excited about the trajectory and future of the company and are thrilled with this recognition. See the announcement here: https://lnkd.in/eUShge_T #EOYUS #EOYPACSW
-
Join Iambic’s CEO Thomas Miller at the BIO International Convention in San Diego, along with Lee Cronin, Raphael Townshend, and Ayman AlAbdallah, for what will be a compelling and insightful discussion on how increasingly sophisticated AI models are enabling the rapid discovery and clinical advancement of highly differentiated drug candidates. Information on the June 5th panel, New Tools, New Times: Chemical and Structural AI for Drug Discovery, can be found here: https://lnkd.in/eqaxWV-u #BIO2024 #drugdiscovery #AI
-
-
Our team is looking forward to #ASCO24 in Chicago, where we will share details of our ongoing Phase 1 study of IAM1363, a highly selective and brain-penetrant HER2 inhibitor, and discuss Iambic’s AI-driven drug discovery platform that enabled us to rapidly identify this clinical candidate. https://lnkd.in/eZe-Dp78
-